Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

nical data and patient and physician preference. We are convinced that physicians and patients will continue to choose PEGASYS/ribavirin combination therapy based on positive experience and sound clinical evidence," said George Abercrombie, President and CEO, Hoffmann-La Roche. "Our current focus at Roche is on advancing the treatment of hepatitis C by optimizing doses and duration of PEGASYS/ribavirin in patients with unmet medical need, while developing new compounds that have the potential to offer a successful outcome to even more patients."

Roche believes that it is critical for patients and physicians to receive complete information to fully understand the results of "IDEAL," so that treatment decisions can be based on sound scientific data.

Please see below for additional information about the "IDEAL" trial, Roche and PEGASYS, including important safety information.

"IDEAL" Trial Design Issues

* Starting doses of ribavirin were different in the Peg-Intron and

PEGASYS arms of the study

* The design calls for a more drastic ribavirin dose reduction for side

effect management in most patients in the PEGASYS arm compared to

patients in the Peg-Intron arms; in some cases, ribavirin dose

reductions for patients in the PEGASYS arm were three times greater

than for patients in the Peg-Intron arms. This is important because a

substantial number of patients being treated for hepatitis C require

their ribavirin dose to be reduced to manage side effects, and this

could have an impact on the efficacy of the regimen

* The PEGASYS arm was not blinded, meaning that patients and physicians

knew which treatment was being administered. Many comparative studies

are blinded to ensure that bias does not compromise the results

* Erythropoetin (EPO) is a medication that is often given to treat

ribavirin-related anemia and help pat
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 ieCrowd™ today announced the ... development of the company,s supplemental oxygen delivery device, ... being developed by ieCrowd,s subsidiary Smart Oxygen Solutions ... demand for oxygen based on level of activity.  ... for the Smart Oxygen device would require a ...
(Date:8/27/2015)... , Aug. 27, 2015  Now that Intuitive ... Da Vinci S™ surgical robot, hospitals with robotic surgery ... They also need to see where they stand with ... the right patients? Have they adopted best practices for ... program in the future? ECRI Institute, which ...
(Date:8/27/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), ... tissue and patent-protected processes to develop and market ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... multiple inaccuracies in the press release issued by ... rulings from the Patent Trial and Appeal Board ...
Breaking Medicine Technology:Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
... announced today the company has reached another major milestone ... management team roster. DiFUSION Technologies is ... commercialization of its proprietary CleanFUZE ™ anti-microbial technology ... line of Posterior Interbody products. "In ...
... supplier of comprehensive patient management solutions, today introduced its ... TrendSetter collects patient compliance data from any brand of ... to home health providers. This allows the providers to ... Other solutions only work for single brands of PAP ...
Cached Medicine Technology:DiFUSION Technologies Adds Accomplished Senior Management Team 2DiFUSION Technologies Adds Accomplished Senior Management Team 3DiFUSION Technologies Adds Accomplished Senior Management Team 4DiFUSION Technologies Adds Accomplished Senior Management Team 5
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering music ... second year to the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. ... to support music education in the underfunded school districts of Mendon and its neighboring ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman of ... The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... XTENT, Inc.,(Nasdaq: XTNT ) today reported financial results for ... company reported a net loss and net loss attributable to ... fourth quarter,of 2007, compared to a net loss and net ... share, for the same period in,2006. The company,s net loss ...
... , , TUESDAY, Feb. 19 (HealthDay News) -- Studies show no ... the sudden collapse of kidney function that carries with it ... analysis of 38 trials found no difference in the death ... method or another, according to a report in the ...
... reaction to sounds, might be way to spot hearing problems, study ... not just be a window to the soul, they may also ... , A new study reports that the eyes can provide clues ... may be especially helpful for diagnosing hearing problems in babies, very ...
... isotopes for peacetime uses at Oak Ridge National Laboratory ... by the American Chemical Society in a special ceremony ... Bruce E. Bursten, Ph.D., president of the Society, will ... director of ORNL. Bursten said the distribution of radioisotopes, ...
... Current Hospital, WALLA WALLA, Wash., Feb. 19 ... announced today the Department of,Veterans Affairs (VA) will ... health at the Walla Walla VA,Medical Center., ... the health care,needs of Washington,s veterans and recognizes ...
... Middle-aged women who suffered physical or sexual abuse as ... costs, according to a long-term study of more than 3,000 ... used health services at significantly higher rates than did non-abused ... with an average age in their late 40s still suffer ...
Cached Medicine News:Health News:XTENT Announces 2007 Financial Results 2Health News:XTENT Announces 2007 Financial Results 3Health News:XTENT Announces 2007 Financial Results 4Health News:XTENT Announces 2007 Financial Results 5Health News:XTENT Announces 2007 Financial Results 6Health News:No Difference Found in Treatments for Acute Kidney Failure 2Health News:No Difference Found in Treatments for Acute Kidney Failure 3Health News:Eyes a Window to Hearing Loss? 2Health News:Eyes a Window to Hearing Loss? 3Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3Health News:Women who suffered child abuse spend more on health care 2Health News:Women who suffered child abuse spend more on health care 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: